DOI: https://doi.org/10.22141/oncology.2.1.2019.165446

The place of target drug cabozantinib in the treatment of metastatic clear cell adenocarcinoma

P.H. Yakovlev

Abstract


The article presents data from recent clinical studies on the advantages of prescribing targeted drug cabozantinib, MET, AXL tyrosine kinase inhibitors, vascular endothelial growth factor receptors, in the treatment of metastatic clear cell carcinoma in both second- and first-line therapy.

Keywords


metastatic clear cell carcinoma; targeted therapy; tyrosine kinase inhibitor; vascular endothelial growth factor receptor inhibitor; survival rate

References


Федоренко З.П., Гулак Л.О., Михайлович Ю.Й. та ін. Рак в Україні, 2016–2017. Захворюваність, смертність, показники діяльності онкологічної служби // Бюлетень Національного канцер-реєстру України № 19. — Національний інститут раку, 2018.

Motzer R.J., Jonasch E., Agarwal N. et al. NCCN Clinical Practice Guidelines in Oncology // Kidney Cancer. Version 2. 2019. — September 17, 2018.

Jonasch E. Updates to the Management of Kidney Cancer // J. Natl. Compr. Canc. Netw. — 2018. — 16. — 639-41.

Vaishampayan U.N. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies // Am. Soc. Clin. Oncol. Educ. Book. — 2016. — 35. — e16-20.

Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma // J. Clin. Oncol. — 2002. — 20. — 289-96.

Heng D.Y., Xie W., Regan M.M., Warren M.A., Gols­hayan A.R., Sahi C. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J. Clin. Oncol. — 2009. — 27. — 5794-9.

Agarwal N., Nussenzveig R., Pal S.K. Biomarkers in renal-cell carcinoma: building on clinical paradigms // Lancet Oncol. — 2018. — 19. — 1560-1.

Muglia V.F., Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings // Radiol. Bras. — 2015. — 48. — 166-74.

Stone L. Kidney cancer: Activation of oncogenes driven by VHL loss in ccRCC // Nat. Rev. Urol. — 2017. — 14. — 637.

Rosenblatt J., McDermott D.F. Immunotherapy for renal cell carcinoma // Hematol. Oncol. Clin. North Am. — 2011. — 25. — 793-812.

Porta C., Szczylik C., Escudier B. Combination or sequen­cing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review // Crit. Rev. Oncol. Hematol. — 2012. — 82. — 323-37.

Roviello G., Zanotti L., Correale P., Gobbi A., Wigfield S., Guglielmi A. et al. Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? // Immunotherapy. — 2017. — 9. — 25-32.

Cabozantinib approved for first-line treatment of advanced renal cell carcinoma // Clin. Adv. Hematol. Oncol. — 2018. — 16. — 96.

Abdelaziz A., Vaishampayan U. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms // Curr. Treat. Options. Oncol. — 2017. — 18. — 18.

Vecchio S.J.D., Ellis R.J. Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma // J. Kidney Cancer VHL. — 2018. — 5. — 1-5.

Abdelaziz A., Vaishampayan U. Cabozantinib for the treatment of kidney cancer // Expert. Rev. Anticancer. Ther. — 2017. — 17. — 577-84.

Neuwelt A.J., Mathur S., Johnson A.T., Kessler E.R., Bowles D.W. Cabozantinib use in renal cell carcinoma // Drugs Today (Barc). — 2017. — 53. — 299-307.

Amzal B., Fu S., Meng J., Lister J., Karcher H. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma // PLoS One. — 2017. — 12. — e0184423.

Choueiri T.K., Halabi S., Sanford B.L., Hahn O., Michaelson M.D., Walsh M.K. et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN ­Trial // J. Clin. Oncol. — 2017. — 35. — 591-7.

Atkins M.B., Tannir N.M. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma // Cancer. Treat. Rev. — 2018. — 70. — 127-37.

Jonasch E. Incorporating New Systemic Therapies in Kidney Cancer Treatment // J. Natl. Compr. Canc. Netw. — 2017. — 15. — 703-5.

Gallardo E., Méndez-Vidal M.J., Pérez-Gracia J.L., Sepúl­veda-Sánchez J.M., Campayo M., Chirivella-González I. et al. SEOM clinical guideline for treatment of kidney cancer (2017) // Clin. Transl. Oncol. — 2018. — 20. — 47-56.

Bersanelli M., Leonardi F., Buti S. Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date // Cancer. Manag. Res. — 2018. — 10. — 3773-80.

Zhang Q., Tian K., Xu J., Zhang H., Li L., Fu Q. et al. Sy­nergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma // J. Immunol Res. — 2017. — 2017. — 6915912.

Powles T., Albiges L., Staehler M., Bensalah K., Dabestani S., Giles R.H. et al. Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer // Eur. Urol. — 2017.

Escudier B., Lougheed J.C., Albiges L. Cabozantinib for the treatment of renal cell carcinoma // Expert. Opin. Pharmacother. — 2016. — 17. — 2499-504.

Yu S.S., Quinn D.I., Dorff T.B. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection // Onco Targets Ther. — 2016. — 9. — 5825-37.

Xie Z., Lee Y.H., Boeke M., Jilaveanu L.B., Liu Z., Bottaro D.P. et al. MET Inhibition in Clear Cell Renal Cell Carcinoma // J. Cancer. — 2016. — 7. — 1205-14.

Wiecek W., Karcher H. Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma // PLoS One. — 2016. — 11. — e0155389.

Cochin V., Gross-Goupil M., Ravaud A., Godbert Y., Le Moulec S. Cabozantinib: Mechanism of action, efficacy and indications // Bull. Cancer. — 2017. — 104. — 393-401.

Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma // Curr. Oncol. Rep. — 2013. — 15. — 76-82.

Choueiri T.K., Escudier B., Powles T., Tannir N.M., Mainwaring P.N., Rini B.I. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial // Lancet Oncol. — 2016. — 17. — 917-27.

Choueiri T.K., Escudier B., Powles T., Mainwaring P.N., Rini B.I., Donskov F. et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma // N. Engl. J. Med. — 2015. — 373. — 1814-23.

Escudier B., Powles T., Motzer R.J., Olencki T., Arén Frontera O., Oudard S. et al. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial // J. Clin. Oncol. — 2018. — 36. — 765-72.

Al-Salama Z.T., Keating G.M. Cabozantinib: A Review in Advanced Renal Cell Carcinoma // Drugs. — 2016. — 76. — 1771-8.

Meng J., Lister J., Vataire A.L., Casciano R., Dinet J. Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England // Clinicoecon. Outcomes Res. — 2018. — 10. — 243-50.

Motzer R.J., Escudier B., Powles T., Scheffold C., Choueiri T.K. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma // Br. J. Cancer. — 2018. — 118. — 1176-8.

Powles T., Motzer R.J., Escudier B., Pal S., Kollmannsber­ger C., Pikiel J. et al. Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma // Br. J. Cancer. — 2018. — 119. — 663-9.

Cella D., Escudier B., Tannir N.M., Powles T., Donskov F., Peltola K. et al. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial // J. Clin. Oncol. — 2018. — 36. — 757-64.

Crist M., Hansen E., Chablani L., Guancial E. Examining the bleeding incidences associated with targeted therapies used in me­tastatic renal cell carcinoma // Crit. Rev. Oncol. Hematol. — 2017. — 120. — 151-62.

De Lisi D., De Giorgi U., Lolli C., Schepisi G., Conteduca V., Menna C. et al. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? // Expert. Opin. Drug Metab. Toxicol. — 2018. — 14. — 461-7.

Miyake H., Imai S., Harada K., Fujisawa M. Absence of Significant Correlation of Adverse Events Between First- and Se­cond-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma // Clin. Genitourin. Cancer. — 2016. — 14. — e19-24.

Rini B.I. Current and emerging first-line systemic therapies in clear cell renal cell carcinoma // Clin. Adv. Hematol. Oncol. — 2018. — 16. — 115-7.

Duran I., Lambea J., Maroto P., González-Larriba J.L., Flores L., Granados-Principal S. et al. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action // Target Oncol. — 2017. — 12. — 19-35.

D'Cunha R., Bae S., Murry D.J., An G. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux // Biopharm. Drug Dispos. — 2016. — 37. — 397-408.

Rexer H., Bedke J. First-line therapy in advanced renal cell carcinoma: A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) — AN 39/16 of the AUO // Urologe A. — 2017. — 56. — 385-6.

Atkins M.B., Plimack E.R., Puzanov I., Fishman M.N., McDermott D.F., Cho D.C. et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial // Lancet Oncol. — 2018. — 19. — 405-15.

Axitinib plus Pembrolizumab Is Effective in Renal Cell Carcinoma // Cancer. Discov. — 2018. — 8. — OF6.

Rothermundt C., Hader C., Gillessen S. Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer // Ann. Oncol. — 2016. — 27. — 544-5.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Practical oncology

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта